… Long-acting bronchodilators are recommended as maintenance therapy for chronic obstructive
pulmonary disease (COPD… to evaluate its potential as a novel treatment option in COPD. …

… to show that novel treatments are … asthma-COPD overlap (ACO) should be abandoned
because it does not identify a clearly independent disease entity and rather indicates asthmatic …

… for COPD maintenance therapy based on COPD … Long-acting bronchodilators (with a
duration of action up to 24 h), such as long-acting muscarinic antagonists (LAMAs) and long-acting …

… antimuscarinic bronchodilator. AZD9164 was the first … program for a novel LAMA to treat
patients with COPD. AZD9164 is … mild persistent asthma and moderate to severe COPD and also …

… of small airways in COPD and asthma has warranted research … mainstay of COPD treatment
is represented by long-acting β … GLY administered using the novel eFlow® CS nebulizer was …

… a history of asthma, nearly 3 months in acute exacerbation, or had a cardiac complication;
2) the experimental group was a noninhaled long-acting bronchodilator and the intervention …

… evidence that long-acting bronchodilators can decrease cough frequency in patients with
COPD, … Characteristics of reversible and nonreversible COPD and asthma and COPD overlap …

… Use of LABAs and LAMAs in patients with COPD, however, … LABAs and LAMAs in management
of COPD, and analyzed the … cardiovascular safety of inhaled long-acting bronchodilators. …

… A nebulized ICS (budesonide) is available for the treatment of patients with asthma. Citation52
Other … This novel bronchoselective LAMA offers patients with COPD who require or prefer …

… Main exclusion criteria were asthma, chronic hypoxaemia, and the occurrence of a
COPD exacerbation in the six weeks before inclusion. Maintenance concomitant inhaled …